The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. is progressing OCU400, a gene therapy designed to address multiple mutations causing retinitis pigmentosa, toward a planned Biologics License Application (BLA) submission this year.
The therapy is distinguished by its aim to treat various genetic forms of the condition through a single, potentially one-time administration. Ocugen, Inc. continues to provide updates as the development moves closer to regulatory review.
Ocugen previously launched a modifier gene therapy platform targeting inherited blindness and presented updates at three industry conferences, according to an earlier summary here. The company has also advanced an early-stage gene therapy for Stargardt disease, addressing a patient group lacking FDA-approved treatments here. These initiatives position Ocugen among firms developing solutions for advanced retinal diseases.